Appendix 2—table 3. Hazard ratios for heart diseases by different adjuvant therapies and time since diagnosis.
| HR (95% CI) for arrhythmia | HR (95% CI) for heart failure | HR (95% CI) for ischemic heart disease | ||||
|---|---|---|---|---|---|---|
| Treatment variables | <10 years | >10 years | <10 years | >10 years | <10 years | >10 years |
| Radiotherapy | ||||||
| Right-sided | REF (1.00) | REF (1.00) | REF (1.00) | REF (1.00) | REF (1.00) | REF (1.00) |
| Left-sided | 0.99 (0.79–1.24) | 0.80 (0.57–1.14) | 1.13 (0.77–1.66) | 0.94 (0.56–1.56) | 1.13 (0.84–1.53) | 1.29 (0.70–2.37) |
| Both-sided | 0.26 (0.04–1.90) | 1.01 (0.30–3.36) | 1.49 (0.36–6.24) | 2.37 (0.54–10.41) | 0.84 (0.20–3.43) | 1.64 (0.21–12.89) |
| Chemotherapy | ||||||
| No | REF (1.00) | REF (1.00) | REF (1.00) | REF (1.00) | REF (1.00) | REF (1.00) |
| Anthracyclines-based | 1.08 (0.81–1.46) | 1.07 (0.65–1.76) | 1.75 (1.11–2.76) | 1.66 (0.86–3.19) | 1.27 (0.87–1.85) | 1.36 (0.60–3.09) |
| Anthracyclines + taxanes | 1.02 (0.51–2.01) | 0.87 (0.13–5.77) | 3.72 (1.72–8.03) | 0.00 (0.00–0.00) | 1.38 (0.60–3.18) | 0.00 (0.00–0.00) |
| CMF | 1.24 (0.59–2.61) | 0.74 (0.18–3.15) | 1.16 (0.33–4.05) | 0.00 (0.00–0.00) | 0.97 (0.33–2.84) | 1.17 (0.16–8.41) |
| Hormone therapy | ||||||
| No | REF (1.00) | REF (1.00) | REF (1.00) | REF (1.00) | REF (1.00) | REF (1.00) |
| Tamoxifen | 0.91 (0.67–1.23) | 1.08 (0.67–1.73) | 0.76 (0.49–1.20) | 0.98 (0.52–1.84) | 0.93 (0.62–1.39) | 1.50 (0.64–3.53) |
| Aromatase inhibitors | 0.97 (0.70–1.36) | 1.05 (0.56–1.95) | 0.93 (0.58–1.49) | 1.47 (0.66–3.27) | 1.47 (0.96–2.24) | 1.31 (0.43–4.01) |
| Trastuzumab * | ||||||
| No | REF (1.00) | REF (1.00) | REF (1.00) | REF (1.00) | REF (1.00) | REF (1.00) |
| Yes | 1.56 (0.82–2.97) | 0.00 (0.00–0.00) | 2.60 (1.14–5.89) | 0.00 (0.00–0.00) | 1.71 (0.76–3.87) | 6.95 (0.56–85.58) |
HR = hazard ratio; CI = confidence interval. Hazard ratios are estimated from Cox proportional hazards models with time since diagnosis as underlying time scale. Hazard ratios are multivariable adjusted including age at diagnosis, year of diagnosis, menopausal status, Charlson comorbidity index, clinical stage, type of surgery, hypertension, chronic pulmonary disease and tobacco abuse, and all treatment variables listed in the table. * Treatment-specific analysis of trastuzumab was restricted to patients diagnosed between 2005 and 2008.